Photocure ASA Reports Strong Growth for First Quarter of 2026#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong Growth for First Quarter of 2026
Photocure ASA announced impressive revenue growth in Q1 2026, driven by product expansion and strategic initiatives in bladder cancer management.
third-news.com
May 7, 2026 at 9:18 AM
Photocure ASA Reports Strong Growth for First Quarter of 2026#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong First Quarter Performance for 2026#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong First Quarter Performance for 2026
Photocure ASA achieved impressive revenue growth in Q1 2026 driven by enhanced adoption of its innovative cancer detection technologies, reflecting strong operational execution across markets.
third-news.com
May 7, 2026 at 6:17 AM
Photocure ASA Reports Strong First Quarter Performance for 2026#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong Q1 2026 Results with Growth in Revenues and Strategic Advancements#Norway#Oslo#Photocure_ASA#Hexvix#BLC_Technology
Photocure ASA Reports Strong Q1 2026 Results with Growth in Revenues and Strategic Advancements
Photocure ASA unveiled impressive Q1 2026 results, with significant revenue growth driven by strategic expansions in blue-light cystoscopy and regulatory advancements, signaling a strong future.
third-news.com
May 7, 2026 at 6:28 AM
Photocure ASA Reports Strong Q1 2026 Results with Growth in Revenues and Strategic Advancements#Norway#Oslo#Photocure_ASA#Hexvix#BLC_Technology
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix_Cysview
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress
Photocure ASA has announced its financial outcomes for Q2 2026, highlighting growth in Hexvix®/Cysview® revenues and strategic milestones in bladder cancer diagnostics.
third-news.com
July 29, 2026 at 6:43 AM
Photocure ASA Reports Second Quarter 2026 Financial Results and Strategic Progress#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix_Cysview
Photocure ASA Reports Strong Revenue Growth for Q2 2026 with Exciting Future Prospects#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong Revenue Growth for Q2 2026 with Exciting Future Prospects
In its Q2 2026 financial report, Photocure ASA revealed impressive growth in revenues and advancements in bladder cancer diagnostics, with exciting future plans.
third-news.com
July 29, 2026 at 6:30 AM
Photocure ASA Reports Strong Revenue Growth for Q2 2026 with Exciting Future Prospects#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care#Norway#Oslo#Bladder_Cancer#Photocure#Hexvix
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care
At the EAU 2026 Congress, Photocure presented innovative trials focusing on personalized treatments for bladder cancer, enhancing patient outcomes through advanced methodologies.
third-news.com
March 16, 2026 at 4:52 PM
Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care#Norway#Oslo#Bladder_Cancer#Photocure#Hexvix
Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth
Photocure ASA has announced strong financial results for Q3 2025, showcasing significant revenue growth and strategic partnerships aimed at enhancing bladder cancer detection.
third-news.com
October 29, 2025 at 6:41 AM
Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook
Photocure ASA highlights strong financial performance in Q3 2025, with increasing revenues and the advent of strategic partnerships for growth. Looking ahead, they anticipate sustained growth in bladder cancer diagnostics.
third-news.com
October 29, 2025 at 6:29 AM
Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales#Norway#Oslo#Bladder_Cancer#Photocure#Hexvix
Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales
Photocure ASA has reported impressive growth for Q1 2025, with revenues of NOK 125.3 million and a focus on expanding bladder cancer treatments using innovative technologies.
third-news.com
May 8, 2025 at 5:22 AM
Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales#Norway#Oslo#Bladder_Cancer#Photocure#Hexvix
Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix
Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments
Photocure ASA has announced a revenue increase for Hexvix®/Cysview® in Q1 2025. With strong performance in Europe and North America, growth looks promising for the year ahead.
third-news.com
May 8, 2025 at 5:10 AM
Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments#Norway#Oslo#Bladder_Cancer#Photocure_ASA#Hexvix
Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment#Photocure_ASA#Blue_Light_Cystoscopy#Hexvix
Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment
At the EAU 2025 congress, Photocure ASA highlights significant advantages of Blue Light Cystoscopy in managing bladder cancer and reducing recurrence rates.
third-news.com
March 24, 2025 at 5:27 PM
Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment#Photocure_ASA#Blue_Light_Cystoscopy#Hexvix
Photocure ASA Reports Robust Financial Performance in Q4 2024#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure ASA Reports Robust Financial Performance in Q4 2024
Photocure ASA showcases impressive revenue growth in Q4 2024, driven by rising sales of Hexvix®/Cysview®. The company anticipates continued momentum through 2025.
third-news.com
February 19, 2025 at 7:31 AM
Photocure ASA Reports Robust Financial Performance in Q4 2024#Norway#Oslo#Photocure_ASA#Hexvix#Cysview
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
www.viv-media.com/infozx-34524...
www.viv-media.com/infozx-34524...
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
www.viv-media.com
September 27, 2024 at 3:06 PM
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
www.viv-media.com/infozx-34524...
www.viv-media.com/infozx-34524...
Photocure demonstrates continued growth with its Q4 2025 results. Hexvix/Cysview revenues reached NOK 135.1 million, while commercial EBITDA more than doubled to NOK 8.4 million. The company projects 7-11% product revenue growth for 2026. #Photocure #LifeScience
February 18, 2026 at 7:10 AM
Photocure demonstrates continued growth with its Q4 2025 results. Hexvix/Cysview revenues reached NOK 135.1 million, while commercial EBITDA more than doubled to NOK 8.4 million. The company projects 7-11% product revenue growth for 2026. #Photocure #LifeScience
Thoughts on this? >> Photocure ASA: Results for the second quarter of
2025 >> Comment below! #AI #healthtech #mhealth #industry40 #IoT
2025 >> Comment below! #AI #healthtech #mhealth #industry40 #IoT
Photocure ASA: Results for the second quarter of
2025
OSLO, Norway, July 30, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and an EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. Photocure expects product …
dlvr.it
July 30, 2025 at 5:54 AM
Thoughts on this? >> Photocure ASA: Results for the second quarter of
2025 >> Comment below! #AI #healthtech #mhealth #industry40 #IoT
2025 >> Comment below! #AI #healthtech #mhealth #industry40 #IoT